Terrie Curran
Chief Executive Officer at PHATHOM PHARMACEUTICALS, INC.
Net worth: 1 M $ as of 2024-04-29
Terrie Curran active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PHATHOM PHARMACEUTICALS, INC. | Director/Board Member | 2019-07-31 | - |
| Chief Executive Officer | 2019-12-01 | - | |
| President | 2019-07-31 | - | |
| ARCUTIS BIOTHERAPEUTICS, INC. | Director/Board Member | 2020-11-01 | - |
| Independent Dir/Board Member | 2020-11-01 | - | |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Director/Board Member | - | - |
Career history of Terrie Curran
Former positions of Terrie Curran
| Companies | Position | Start | End |
|---|---|---|---|
| MYOVANT SCIENCES LTD. | Director/Board Member | 2016-11-15 | 2023-03-09 |
| Independent Dir/Board Member | 2016-11-15 | 2023-03-09 | |
| CELGENE | Corporate Officer/Principal | 2012-12-31 | 2019-08-31 |
| H. LUNDBECK A/S | Director/Board Member | 2014-03-03 | 2017-02-28 |
| Independent Dir/Board Member | 2014-03-03 | 2017-02-28 | |
| MERCK & CO., INC. | Corporate Officer/Principal | 2009-10-31 | 2013-03-31 |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | 2003-02-28 | 2007-03-31 |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Director/Board Member | 2018-01-31 | - |
Training of Terrie Curran
| University of Technology Sydney | Undergraduate Degree |
Statistics
International
| United States | 8 |
| Denmark | 2 |
| United Kingdom | 2 |
Operational
| Director/Board Member | 6 |
| Corporate Officer/Principal | 3 |
| Independent Dir/Board Member | 3 |
Sectoral
| Health Technology | 9 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| H. LUNDBECK A/S | Health Technology |
| MERCK & CO., INC. | Health Technology |
| PHATHOM PHARMACEUTICALS, INC. | Health Technology |
| ARCUTIS BIOTHERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Commercial Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Terrie Curran
- Experience
